[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507447":3},{"organization":4,"outcomesModule":7,"designInfo":41,"detailedDescription":11,"studyPopulation":11,"armGroups":52,"interventions":65,"overallOfficials":11,"centralContacts":75,"locations":11,"responsibleParty":82,"collaborators":11,"id":84,"slug":11,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":11,"eligibilityCriteria":88,"healthyVolunteers":85,"sex":89,"minAge":90,"maxAge":11,"enrollmentInfo":91,"targetDuration":11,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":102,"overallStatus":106,"whyStopped":11,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":11},{"fullName":5,"class":6},"Taoyuan General Hospital","OTHER_GOV",{"primaryOutcomes":8,"secondaryOutcomes":22,"otherOutcomes":11},[9,13,16,18,20],{"measure":10,"description":11,"timeFrame":12},"Whether there is an association between 25(OH)D and PTH: positive or negative association , or no association",null,"During the study period",{"measure":14,"description":11,"timeFrame":15},"Ratio of liver failure","7 days pre- OP (day -7)",{"measure":14,"description":11,"timeFrame":17},"1 day pre- OP (day -1)",{"measure":14,"description":11,"timeFrame":19},"1 day post- OP (day 1)",{"measure":14,"description":11,"timeFrame":21},"1 day before discharge",[23,26,28,30,32,35,38],{"measure":24,"description":11,"timeFrame":25},"25(OH)D status","Baseline (day -7), day -1, day 1 and 1 day before discharge",{"measure":27,"description":11,"timeFrame":25},"Prevalence of high PTH",{"measure":29,"description":11,"timeFrame":25},"Prevalence of hypercalcemia",{"measure":31,"description":11,"timeFrame":25},"Prevalence of hypomagnesemia",{"measure":33,"description":11,"timeFrame":34},"30-day mortality","day 1 post-OP and 1 day before discharge",{"measure":36,"description":37,"timeFrame":34},"Clinical outcomes","Including level of C-reactive protein and white blood cell (WBC) count",{"measure":39,"description":40,"timeFrame":34},"Complications after surgery","Including in-hospital infectious complications, Dindo-Clavien classification, volume of ascites, duration of ascites, intra-abdominal abscess, postoperative haemorrhage, pleural effusion, wall abscess, and eventration.",{"allocation":42,"interventionModel":43,"interventionModelDescription":11,"primaryPurpose":44,"observationalModel":11,"timePerspective":11,"maskingInfo":45},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":46,"maskingDescription":11,"whoMasked":47},"QUADRUPLE",[48,49,50,51],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[53,59],{"label":54,"type":55,"description":56,"interventionNames":57},"Vitamin D group","EXPERIMENTAL","Oral supplementation of 1,728,000 IU vitamin D3 in 3 days",[58],"Other: Vitamin D",{"label":60,"type":61,"description":62,"interventionNames":63},"Placebo Group","PLACEBO_COMPARATOR","Oral supplementation of placebo in 3 days",[64],"Other: Placebo",[66,71],{"type":67,"name":68,"description":69,"armGroupLabels":70,"otherNames":11},"OTHER","Vitamin D","Oral supplementation of 576,000IU\u002Fday vitamin D3 in 3 consecutive days",[54],{"type":67,"name":72,"description":73,"armGroupLabels":74,"otherNames":11},"Placebo","Oral supplementation of placebo in 3 consecutive days.",[60],[76],{"name":77,"role":78,"phone":79,"phoneExt":80,"email":81},"Yuan-Hao Ku, MD","CONTACT","+886-3 3699721","4208","darkbravo@gmail.com",{"type":83,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100507447",false,"NCT05887505","Effects of Vitamin D Status and Multiple Mega-dose Supplementation on Health Care Disparities in Perioperative Patients With Hepatocellular Carcinoma Receiving Hepatectomy","Inclusion Criteria:\n\n* 1\\. ≥ 20-year HCC subjects receiving laparoscopic hepatectomy\n* 2.Sign the informed consent\n\nExclusion Criteria:\n\n* 1\\. Using estrogen drugs, bisphosphonates, or drugs for bone disease.\n* 2\\. Consume calcium tablets within 2 weeks before operation\n* 3\\. Sarcoidosis, multiple myeloma\n* 4\\. Pregnant women or plan to become pregnant within 3 months after surgery\n* 5\\. Autoimmune hepatitis (AIH)\n* 6\\. Early liver recurrence\n* 7\\. Used to participate in other clinical trials","ALL","20 Years",{"count":92,"type":93},120,"ESTIMATED","INTERVENTIONAL",[96],"NA","High concentrations of parathyroid hormone (PTH) are common in patients with hepatocellular carcinoma (HCC). This study is aimed to investigate effects of vitamin D status and its multiple mega-dosage supplementation on PTH and clinical outcomes in HCC patients before and after hepatectomy. It's a single-center, prospective, parallel, double-blind, placebo-controlled study for 120 eligible subjects. The subjects will receive consecutively 3-day intervention treatments from 7th day before surgery. 30-day postoperative mortality, postoperative complications, and laboratory data will be evaluated.",[99,100,101],"Hepatocellular Carcinoma","Liver Function","Postoperative Complications",[103,104,105],"Vitamin D Supplementation","Hepatectomy","Perioperative","NOT_YET_RECRUITING","2023-06-04",{"date":109,"type":110},"2023-06-06","ACTUAL",{"date":112,"type":93},"2023-06-09",{"date":114,"type":93},"2027-12-31",{"name":5,"class":6}]